


PRODUCT INFORMATION



Mirabegron

Item No. 17319

CAS Registry No.: 223673-61-8
Formal Name: 2-amino-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-4-thiazoleacetamide
Synonym: YM-178
MF: C₂₁H₂₄N₄O₂S
FW: 396.5
Purity: ≥98%
UV/Vis.: λ_{max}: 250 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Mirabegron is supplied as a crystalline solid. A stock solution may be made by dissolving the mirabegron in the solvent of choice, which should be purged with an inert gas. Mirabegron is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of mirabegron in ethanol is approximately 3 mg/ml and approximately 5 mg/ml in DMSO and DMF.

Mirabegron is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, mirabegron should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Mirabegron has a solubility of approximately 0.1 mg/ml in a 1:6 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Mirabegron is an agonist of the β₃-adrenergic receptor (β₃-AR).¹ It induces cAMP accumulation in CHO cells expressing the β₃-AR but not the β₁- or β₂-AR (EC₅₀s = 0.0224, >10, and >10 μM, respectively). Mirabegron reduces contraction induced by carbamoylcholine (Item No. 14486) of isolated rat and human bladder strips (EC₅₀s = 5.1 and 0.78 μM, respectively). It decreases the frequency of isovolumetric rhythmic bladder contractions in anesthetized rats when administered at a dose 3 mg/kg. Formulations containing mirabegron have been used in the treatment of overactive bladder.

Reference

1. Takasu, T., Ukai, M., Sato, S., *et al.* Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective β₃-adrenoceptor agonist, on bladder function. *J. Pharmacol. Exp. Ther.* **321**(2), 642-647 (2007).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/26/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM